Avidity Biosciences Inc
RNAM
Rank in Stocks
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Share Price
$71.34
Last synced: 2026-03-03
Market Cap
$9.84B
Change (1 day)
0.00%
Change (1 year)
-
Country
US
Trade Avidity Biosciences Inc (RNAM)
Category
Healthcare
P/B ratio for Avidity Biosciences Inc (RNAM)
P/B ratio as of October 2026 TTM: 6.44
According to Avidity Biosciences Inc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 6.44. At the end of 2024 the company had a P/B ratio of 5.69.
P/B ratio history for Avidity Biosciences Inc from 2018 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 6.44 | 8.80% |
| 2025 | 5.92 | 4.15% |
| 2024 | 5.69 | -46.29% |
| 2023 | 10.59 | 61.58% |
| 2022 | 6.55 | -16.92% |
| 2021 | 7.89 | 53.53% |
| 2020 | 5.14 | -112.32% |
| 2019 | -41.71 | -37.04% |
| 2018 | -66.25 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -2.95% |
US
|
|
| 13.6307 | 111.63% |
US
|
|
| 4.4521 | -30.88% |
AU
|
|
| 4.2241 | -34.42% |
BE
|
|
| 6.3632 | -1.21% |
NL
|
